TRIO-TECH INTERNATIONAL (TRT) Stock Fundamental Analysis

USA • NYSE Arca • NYSEARCA:TRT • US8967122057

5.37 USD
-0.17 (-3.07%)
At close: Feb 4, 2026
5.37 USD
0 (0%)
Pre-Market: 2/5/2026, 8:04:44 AM
Fundamental Rating

3

Overall TRT gets a fundamental rating of 3 out of 10. We evaluated TRT against 113 industry peers in the Semiconductors & Semiconductor Equipment industry. While TRT seems to be doing ok healthwise, there are quite some concerns on its profitability. TRT does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

  • TRT had negative earnings in the past year.
  • In the past year TRT had a positive cash flow from operations.
  • In multiple years TRT reported negative net income over the last 5 years.
  • Each year in the past 5 years TRT had a positive operating cash flow.
TRT Yearly Net Income VS EBIT VS OCF VS FCFTRT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2M 4M 6M 8M

1.2 Ratios

  • TRT's Return On Assets of -0.10% is in line compared to the rest of the industry. TRT outperforms 48.67% of its industry peers.
  • The Return On Equity of TRT (-0.12%) is comparable to the rest of the industry.
  • TRT has a Return On Invested Capital (0.34%) which is in line with its industry peers.
  • TRT had an Average Return On Invested Capital over the past 3 years of 2.81%. This is significantly below the industry average of 10.69%.
Industry RankSector Rank
ROA -0.1%
ROE -0.12%
ROIC 0.34%
ROA(3y)2.01%
ROA(5y)2%
ROE(3y)2.82%
ROE(5y)2.96%
ROIC(3y)2.81%
ROIC(5y)N/A
TRT Yearly ROA, ROE, ROICTRT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2 -2 4 6 8

1.3 Margins

  • The Operating Margin of TRT (0.42%) is comparable to the rest of the industry.
  • In the last couple of years the Operating Margin of TRT has declined.
  • TRT has a Gross Margin of 25.07%. This is in the lower half of the industry: TRT underperforms 75.22% of its industry peers.
  • TRT's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 0.42%
PM (TTM) N/A
GM 25.07%
OM growth 3Y-57.25%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.98%
GM growth 5Y3.52%
TRT Yearly Profit, Operating, Gross MarginsTRT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5 10 15 20 25

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), TRT is destroying value.
  • The number of shares outstanding for TRT has been increased compared to 1 year ago.
  • The number of shares outstanding for TRT has been increased compared to 5 years ago.
  • Compared to 1 year ago, TRT has an improved debt to assets ratio.
TRT Yearly Shares OutstandingTRT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1M 2M 3M 4M
TRT Yearly Total Debt VS Total AssetsTRT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M

2.2 Solvency

  • TRT has an Altman-Z score of 4.04. This indicates that TRT is financially healthy and has little risk of bankruptcy at the moment.
  • With a Altman-Z score value of 4.04, TRT perfoms like the industry average, outperforming 54.87% of the companies in the same industry.
  • A Debt/Equity ratio of 0.02 indicates that TRT is not too dependend on debt financing.
  • TRT has a Debt to Equity ratio of 0.02. This is in the better half of the industry: TRT outperforms 69.03% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z 4.04
ROIC/WACC0.03
WACC10.91%
TRT Yearly LT Debt VS Equity VS FCFTRT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M 20M 30M

2.3 Liquidity

  • TRT has a Current Ratio of 5.03. This indicates that TRT is financially healthy and has no problem in meeting its short term obligations.
  • TRT has a better Current ratio (5.03) than 73.45% of its industry peers.
  • A Quick Ratio of 4.67 indicates that TRT has no problem at all paying its short term obligations.
  • The Quick ratio of TRT (4.67) is better than 76.99% of its industry peers.
Industry RankSector Rank
Current Ratio 5.03
Quick Ratio 4.67
TRT Yearly Current Assets VS Current LiabilitesTRT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • The earnings per share for TRT have decreased strongly by -105.27% in the last year.
  • TRT shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -13.81%.
  • Measured over the past years, TRT shows a small growth in Revenue. The Revenue has been growing by 1.14% on average per year.
EPS 1Y (TTM)-105.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20.71%
Revenue 1Y (TTM)-13.81%
Revenue growth 3Y-6.11%
Revenue growth 5Y1.14%
Sales Q2Q%9.49%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TRT Yearly Revenue VS EstimatesTRT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • TRT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TRT Price Earnings VS Forward Price EarningsTRT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

  • TRT's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. TRT is cheaper than 100.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 0.54
TRT Per share dataTRT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for TRT!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TRIO-TECH INTERNATIONAL

NYSEARCA:TRT (2/4/2026, 8:04:00 PM)

Premarket: 5.37 0 (0%)

5.37

-0.17 (-3.07%)

Chartmill FA Rating
GICS IndustryGroupSemiconductors & Semiconductor Equipment
GICS IndustrySemiconductors & Semiconductor Equipment
Earnings (Last)11-10
Earnings (Next)02-11
Inst Owners23.91%
Inst Owner Change0.12%
Ins Owners25.8%
Ins Owner Change0.73%
Market Cap23.36M
Revenue(TTM)36.47M
Net Income(TTM)-41.00K
Analysts0
Price TargetN/A
Short Float %N/A
Short Ratio1.26
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.64
P/FCF N/A
P/OCF 62.96
P/B 0.69
P/tB 0.69
EV/EBITDA 0.54
EPS(TTM)-0.01
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.14
FCFYN/A
OCF(TTM)0.09
OCFY1.59%
SpS8.38
BVpS7.82
TBVpS7.82
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -0.1%
ROE -0.12%
ROCE 0.44%
ROIC 0.34%
ROICexc 0.66%
ROICexgc 0.66%
OM 0.42%
PM (TTM) N/A
GM 25.07%
FCFM N/A
ROA(3y)2.01%
ROA(5y)2%
ROE(3y)2.82%
ROE(5y)2.96%
ROIC(3y)2.81%
ROIC(5y)N/A
ROICexc(3y)5.18%
ROICexc(5y)N/A
ROICexgc(3y)5.18%
ROICexgc(5y)N/A
ROCE(3y)3.55%
ROCE(5y)N/A
ROICexgc growth 3Y-59.08%
ROICexgc growth 5YN/A
ROICexc growth 3Y-59.08%
ROICexc growth 5YN/A
OM growth 3Y-57.25%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.98%
GM growth 5Y3.52%
F-Score4
Asset Turnover0.89
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA 0.2
Cap/Depr 35.28%
Cap/Sales 2.65%
Interest Coverage 3.3
Cash Conversion 12.82%
Profit Quality N/A
Current Ratio 5.03
Quick Ratio 4.67
Altman-Z 4.04
F-Score4
WACC10.91%
ROIC/WACC0.03
Cap/Depr(3y)45.5%
Cap/Depr(5y)44.1%
Cap/Sales(3y)4.78%
Cap/Sales(5y)4.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-105.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20.71%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-13.81%
Revenue growth 3Y-6.11%
Revenue growth 5Y1.14%
Sales Q2Q%9.49%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-86.65%
EBIT growth 3Y-59.86%
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-127.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-86.35%
OCF growth 3Y-44.07%
OCF growth 5Y-34.21%

TRIO-TECH INTERNATIONAL / TRT FAQ

Can you provide the ChartMill fundamental rating for TRIO-TECH INTERNATIONAL?

ChartMill assigns a fundamental rating of 3 / 10 to TRT.


Can you provide the valuation status for TRIO-TECH INTERNATIONAL?

ChartMill assigns a valuation rating of 1 / 10 to TRIO-TECH INTERNATIONAL (TRT). This can be considered as Overvalued.


Can you provide the profitability details for TRIO-TECH INTERNATIONAL?

TRIO-TECH INTERNATIONAL (TRT) has a profitability rating of 3 / 10.


What is the financial health of TRIO-TECH INTERNATIONAL (TRT) stock?

The financial health rating of TRIO-TECH INTERNATIONAL (TRT) is 5 / 10.